skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

Free Extracts: Biomedtracker Q3 2017 Outlook Report

Simply complete the required fields and download your free copy of this important report. The full report includes:


This report comes to you from Biomedtracker, part of the Informa Pharma Intelligence suite of tools. Biomedtracker provides its clients from the pharmaceutical, biotech, and investment industries insight into the likelihood of approval, commercial potential, and future data and regulatory catalysts for drugs within the competitive landscape of every important disease and indication. Biomedtracker is the leader in providing objective information alongside evidence-based clinical assessments and investment research on pipeline drugs worldwide.

Download your report extract today

  • 21 drugs and their expected catalysts for Q3 2017 
  • The likelihood of Phase/PDUFA review success for each drug 
  • The overall likelihood of approval (LOA) given each drug’s phase, drug class, and disease group 
  • The results of Q2 2017 catalysts 
  • A list of large impact catalysts through Q3 2017, also available as an Excel download


  • Biomedtracker: 開発中医薬品をFDA承認確率で評価, Scrip: 世界の医療用医薬品&製薬産業に関するニ...

    39th Annual J.P. Morgan Healthcare Conference 2021

    Keep up with events as they unfold at the 39th Annual J.P. Morgan Annual Healthcare Conference on January 11-14, 2021. Pharma Intelligence and Insights journalists will bring you real time reporting, highlighting important events and key takeaways from every day of the largest and most informative healthcare investment symposium in the industry.

  • ターゲット市場の実像をつかむ, Biomedtracker: 開発中医薬品をFDA承認確率で評価


    By Dustin Phan


    Topics Coronavirus Clinical Trials

  • ターゲット市場の実像をつかむ, Biomedtracker: 開発中医薬品をFDA承認確率で評価

    Gene therapy manufacturers

    Given the transformative nature of regenerative medicines, which can yield greatly improved patient responses, meet unmet need, and now exist as viable products on the market, cell and gene therapeutics developers over the past several years have been drawing deal attention, not only through collaborative partnerships, but also as acquisition targets.